Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Third-party LMP-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational allogeneic cell therapy consisting of third-party latent membrane protein (LMP)-specific cytotoxic T lymphocytes (CTLs) developed by New York Medical College. The therapy is designed to treat Epstein-Barr virus (EBV)-associated malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, and chronic active EBV infection. The CTLs are expanded from healthy donors and trained to recognize and eliminate cells expressing the EBV antigens LMP1 and LMP2, which are frequently expressed in EBV-driven lymphomas. By using "off-the-shelf" third-party cells, the therapy aims to provide a rapid treatment option for patients with refractory or relapsed disease, particularly children, adolescents, and young adults.
- Other names
- EBV CTLsLMP1/2-specific CTLsAllogeneic LMP-specific cytotoxic T lymphocytesThird Party LMP-CTLs
02
Targets
Epstein-Barr virus latent membrane protein 2 peptide–Major Histocompatibility ComplexpMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Third-party LMP-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Third-party LMP-specific cytotoxic T lymphocytes.